Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;5(5):1457-1460.
doi: 10.3892/ol.2013.1247. Epub 2013 Mar 12.

Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report

Kananathan Ratnavelu  1 , Baskar Subramani, Chithra Ramanathan Pullai, Kohila Krishnan, Sheela Devi Sugadan, Manjunath Sadananda Rao, Abhi Veerakumarasivam, Xuewen Deng, Terunuma Hiroshi
Affiliations

Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report

Kananathan Ratnavelu et al. Oncol Lett. 2013 May.

Abstract

Rare types of cancer are often not effectively treated by approaches such as chemotherapy and radio-therapy, although their side-effects persist. Immunotherapy has been gaining attention worldwide with growing examples of its anticancer activity demonstrated in vivo. This case report describes a 35-year-old male who suffered from advanced epithelioid sarcoma and underwent 18 cycles of chemotherapy without any significant response, who suffered adverse effects that caused lung collapse. A notable response was observed following the administration of autologous immune enhancement therapy (AIET), which involves a process of isolation, activation and expansion of natural killer (NK) and T cells, which were obtained from the patient's own (autologous) peripheral blood. With the present data and the response of the patient to AIET, it may be proposed that AIET is beneficial for patients suffering from advanced epithelioid sarcoma without producing adverse effects.

Keywords: T cells; advanced epithelioid sarcoma; adverse reactions; autologous immune enhancement therapy; natural killer cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Stable hemoglobin level during the course of AIET from June 2011 to February 2012. AIET, autologous immune enhancement therapy.
Figure 2
Figure 2
(A) Before administration of AIET, necrotic tissues with severe disease progression were observed. (B) After 3 infusions of AIET, clear healing of the wound was visible. (C) After 6 AIET infusions, significant healing of the wound was observed. AIET, autologous immune enhancement therapy.
Figure 2
Figure 2
(A) Before administration of AIET, necrotic tissues with severe disease progression were observed. (B) After 3 infusions of AIET, clear healing of the wound was visible. (C) After 6 AIET infusions, significant healing of the wound was observed. AIET, autologous immune enhancement therapy.
Figure 2
Figure 2
(A) Before administration of AIET, necrotic tissues with severe disease progression were observed. (B) After 3 infusions of AIET, clear healing of the wound was visible. (C) After 6 AIET infusions, significant healing of the wound was observed. AIET, autologous immune enhancement therapy.
See this image and copyright information in PMC

References

    1. Demetri GD, Baker LH, Benjamin RS, et al. Soft tissue sarcoma. J Natl Compr Canc Netw. 2007;5:364–399. - PubMed
    1. Pedrazzoli P, Secondino S, Perfetti V, Comoli P, Montagna D. Immunotherapeutic Intervention against Sarcomas. J Cancer. 2011;2:350–356. - PMC - PubMed
    1. Ferrari A, Miceli R, Casanova M, et al. The symptom interval in children and adolescents with soft tissue sarcomas. Cancer. 2010;116:177–183. - PubMed
    1. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54:94–109. - PubMed
    1. Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch Surg. 1992;127:1379–1385. - PubMed

LinkOut - more resources